Harvard Apparatus Regenerative Technology (HRGN) Q4 2025 earnings summary

Executive summary

• Clinical-stage biotech focused on regenerative medicine for GI tract and airway disorders, leveraging proprietary stem cell-based technology for organ regeneration, with a lead esophageal implant product in phase 1 clinical trials in the US and China.

• Consumer Health Products segment markets dietary supplements in Asia, with expanded distribution and new product launches driving revenue growth.

• The company has not achieved regulatory approval for any clinical products and continues to incur operating losses, with a substantial accumulated deficit and a going concern qualification from auditors.

Financial highlights

• Product revenue increased 64% year-over-year to $704,000 in 2025, driven by new product launches and expanded distribution in the Consumer Health segment.

• Net loss for 2025 was $6.9 million, an improvement from $7.7 million in 2024.

• Operating expenses decreased 7% to $7.6 million in 2025, with R&D expense up 15% to $2.7 million, and G&A expense down 15% to $4.3 million.

• Accumulated deficit reached $106.6 million as of December 31, 2025.

• Cash and cash equivalents were $1.4 million at year-end 2025, expected to fund operations into Q2 2026.

Outlook and guidance

• Additional capital is required before or during Q2 2026 to continue operations; failure to secure funding may force curtailment or cessation of operations.

• The company expects continued operating losses and negative cash flows as it invests in clinical development and commercialization.

• Strategies to mitigate clinical trial recruitment delays include expanding trial sites and enhancing patient outreach.